Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells

Fig. 6

SRPK1 expression conferred resistance to cisplatin in YT cells. SRPK1 mRNA (A) and protein (B) levels in YT cells was down- and upregulated by siSRPK1-1 and the overexpression plasmid pLVX-SRPK1, respectively. C The sensitivity of YT cells to cisplatin was decreased and increased upon SRPK1 upregulation and downregulation, respectively (mean activity ± SD from quadruplicate wells, *P < 0.05 versus control group). D SPHINX31 and SRPIN340 synergistically enhanced the cytotoxic effects of cisplatin in YT cells (mean activity ± SD from quadruplicate wells, *P < 0.05 compared with the control group).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us